The all-ages incidence of urticaria, age-standardized percent prevalence, and all ages DALYs cases of 2021 in China. by Wenxi Xiao (22145724)

Subjects:

(A) Network map of the top ten anti-AD core targets and the top 30 KEGG pathways. The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 c... by Shakeel Ahmad Khan (13202394)

A Model for MST1-mediated protection in liver fibrosis caused by <i>Schistosoma japonicum</i> infection. by Jianyang Li (461703)

Subjects:

Relationship between τ_<i>i</i> and σ_<i>i</i>. by Zhezhe Zhang (19704587)

“…Under the same <i>JRC</i>, σ_<i>i</i> increases with the increase of τ₁, and Δσ_n decreases with the increasing τ₁. …”

Relationship between τ_<i>i</i> and σ_<i>i</i>. by Zhezhe Zhang (19704587)

“…Under the same <i>JRC</i>, σ_<i>i</i> increases with the increase of τ₁, and Δσ_n decreases with the increasing τ₁. …”

Downregulation of CD36 impaired phagocytic capacity and is associated with a proinflammatory phenotype of <i>Mst1</i> deficiency macrophages. by Jianyang Li (461703)

Subjects:

Table 2_An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.xlsx by Jingkai Di (17792116)

Table 1_An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.docx by Jingkai Di (17792116)

Table 3_An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis.xlsx by Jingkai Di (17792116)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Subjects:

A visual comparison of the associated resistance data from Table 1 with the values of <i>k</i>_cat, <i>K</i>_M, catalytic efficiency (<i>k</i>_cat/<i>... by J. Roadnight Sheehan (20141887)